Fig. 5

Reduced leukemia-initiating cells in Sharp1^−/− MLL-AF6 AML. a Analysis of Leukemic-Granulocyte Macrophage Progenitor (L-GMP). Left panel: a representative flow cytometry plot, pregated on lineage-negative cells, and then on c-kit⁺Sca1^–CD34⁺CD16/32⁺ cells; shown are percentage of total CD45.2⁺ bone marrow (BM) cells. Percentage of the gated populations were shown. Right panel: Graphical presentation of percentage of L-GMP and Lin^–c-kit⁺Sca1^– cells in CD45.2⁺ BM cells. The graph is presented as mean ± s.e.m. b Limiting Dilution Assay (LDA). The indicated numbers of FACS-sorted L-GMP (MLL-AF6 AML Sharp1^+/+ and Sharp1^−/−) cells were transplanted into sublethally irradiated congenic mice. c HSPC and whole bone marrow (WBM) cell number from a femur and a tibia, and percentage of BM mature myeloid cells (Gr1⁺CD11b⁺) and B (B220⁺) are graphed. HSC (hematopoietic stem cell = CD150⁺CD48^–), MPP (multipotent progenitor = CD150^–CD48⁺), GMP (granulocyte-macrophage progenitor = CD34⁺CD16/32⁺), CMP (common myeloid progenitor = CD34⁺CD16/32^–), MEP (megakaryocyte-erythroid progenitor = CD34^–CD16/32^–), CLP (common lymphoid progenitor = IL7R⁺Flk2⁺), and WBM. d 500,000 WBM cells from Sharp1^+/+ or Sharp1^−/− mice were transplanted into irradiated recipient mice along with 500,000 congenic WBM cells as competitor cells. Percentage of donor in peripheral blood was monitored for 16 weeks after transplantation. The graphs are presented as mean ± s.e.m, *p < 0.05